Anti-C5 / C5b antibody [EPR23940-3],Abcam,AB275931

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Host

Rabbit

Reactivity

Mouse, Rat, Human

Application

WB, IHC-P

Platform ID

BAB048387321

Abcam

Headquarters

Discovery Drive Cambridge Biomedical Campus Cambridge CB2 0AX UK

Contact

Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215

Product Specifications
Scientific Background

Specifications

NameAnti-C5 / C5b antibody [EPR23940-3]
Cat. No.AB275931
HostRabbit
IsotypeIgG
ReactivityMouse, Rat, Human
ApplicationWB, IHC-P
ClonalityMonoclonal
Clone NumberEPR23940-3
Concentration0.525 mg/mL Batch dependent concentration
ImmunogenThe exact immunogen used to generate this antibody is proprietary information.
PurityAffinity purification Protein A
Appearance/FormLiquid
ShippingBlue Ice
FormulationPreservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Storage-20°C
Regulatory StatusResearch Use Only

Scientific Background

Target data Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed : 12878586, PubMed : 18204047, PubMed : 30643019, PubMed : 6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed : 12878586, PubMed : 18204047, PubMed : 30643019, PubMed : 39914456, PubMed : 39814882, PubMed : 6554279).. Complement C5b. Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed : 26841837, PubMed : 27052168, PubMed : 30552328, PubMed : 30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex : C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed : 30552328, PubMed : 30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed : 30552328, PubMed : 32569291).. C5a anaphylatoxin. Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed : 8182049, PubMed : 9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed : 36806352, PubMed : 37852260, PubMed : 37169960, PubMed : 8182049, PubMed : 9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed : 342601, PubMed : 37852260, PubMed : 37169960, PubMed : 5765461, PubMed : 8182049, PubMed : 9553099). See full target information C5

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.